Alleviation of fatigue has been emerging as a serious issue that requires urgent attention. Health professionals and sports physiologists have been looking for active natural products and synthetic compounds to overcome fatigue in humans. This study was designed to define the anti-fatigue property of Rubus parvifolius L. (RPL) by characterization of active constituents using a mouse forced swimming test model. Four RPL fractions with different polarities containing anti-fatigue activity were sequentially isolated from the n-butanol RPL extract, followed by elution of 50% ethanol-water fraction from D101 macroporous resin chromatography to obtain nigaichigoside F1, suavissimoside R1 and coreanoside F1. Active constituents of the 50% ethanol-water eluate of RPL were total saponins. The fractions were examined based on the effect on weight-loaded swimming capacity of mice. Serum levels of urea nitrogen (SUN), triglyceride fatty acids (TG), lactate dehydrogenase (LDH), lactic acid (LA), ammonia and hepatic glycogen (HG) were also examined for potential mechanisms underlying the anti-fatigue effect of RPL extracts. During the experiment, two inflammatory markers, interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) in serum, were measured. We found that total saponins from RPL possess potent capabilities to alleviate mouse fatigue induced by forced swimming and that nigaichigoside F1 was responsible for the pharmacological effect. The underlying mechanisms include delays of SUN and LA accumulation, a decrease in TG level by increasing fat consumption, increases in HG and LDH so that lactic acid accumulation and ammonia in the muscle were reduced, and suppression of increased immune activation and inflammatory cytokine production. Our findings will be helpful for functional identification of novel anti-fatigue components from natural medicinal herbs.
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.
Rubus parvifolius L. (Rp) is a medicinal herb that possesses antibacterial activity. In this study, we extracted the volatile oil from the leaves of Rp to assess its antibacterial activity and analyze its chemical composition. A uniform distribution design was used to optimize the extraction procedure, which yielded 0.36% (w/w) of light yellowish oil from the water extract of Rp leaves. We found that the extracted oil effectively inhibited the growth of a wide range of Gram positive and negative bacteria, including Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumanii, Bacillus cloacae, and Klebsiella pneumoniae. We further analyzed the components contained in the hydro-distillated Rp volatile oil by gas chromatography-mass spectroscopy. Twenty nine compounds were identified, including 4-hydroxy-3-methoxystyrene (66%), 3,7,11,15-tetramethyl-2-hexadecen-1-ol (10%) and 4-tert-butylbenzoic acid (2%). Our results suggest that one or multiple constituents contained in Rp volatile oil may account for its antibacterial activity.
7 February 2024 in The American Journal of Tropical Medicine and Hygiene
: Fonsecaea monophora is a species of Fonsecaea that belongs to Chaetothyriales. It is usually isolated from tropical and subtropical regions, causing reactive inflammation, skin abscesses, and pain. Cerebral infection caused by F. monophora is rare but often fatal. Diagnosing this disease at an early stage is difficult, and appropriate antifungal therapy is often delayed as a result. We report the case of a 53-year-old woman with type 2 diabetes who presented with a headache 2 months ago and progressive right-sided weakness of 1 month’s duration. Magnetic resonance imaging revealed a space-occupying lesion in the left frontal lobe and corpus callosum. The cystic mass was removed by surgical intervention, and the identification of the sample based on sequencing of the internal transcribed spaced region in BLAST-N search showed that the sequences producing most significant alignments were F. monophora or similar (query cover 99%, E value 0.0, per ident 99.84). The patient was treated with a 3-month course of twice daily voriconazole, leading to complete recovery.
This study aimed to explore the association between elevated estimated glomerular filtration rate (eGFR) and poor prognosis in pediatric patients with community-acquired bacterial meningitis (BM) receiving vancomycin. This retrospective cohort study included children aged 1 month to 18 years with community-acquired BM admitted to the Department of Neurology, Children's Hospital of Chongqing Medical University (CHCMU) from 2013 to 2023. Relevant information for all patients was collected, and clinical outcomes were assessed using the Glasgow Outcome Scale (GOS) at the time of discharge. Logistic regression analysis, receiver operating characteristic (ROC) curve analysis, integrated discrimination improvement (IDI), net reclassification improvement (NRI) indices, and survival curve analysis were employed to investigate the associations between elevated eGFR and poor clinical outcomes in pediatric patients with community-acquired BM. A total of 119 patients were included. Significant differences in the eGFR were observed among pediatric patients with different prognoses (P < 0.05). The initial vancomycin trough concentration in the elevated eGFR group was significantly lower than that in the normal eGFR group [5.600 (4.590; 8.060) mg/L vs. 9.205 (7.500; 12.070) mg/L]. At discharge, the GOS scores of the two groups also significantly differed (P < 0.05). In the analysis of factors influencing poor prognosis in pediatric patients with BM, an eGFR ≥ 169.21 mL/min/1.73 m2 was identified as an important factor associated with poor clinical outcomes in both univariate and multivariate analyses. Incorporating the elevated eGFR factor into the predictive model significantly improved its diagnostic performance (NRI 0.624, P = 0.00297; IDI 0.1057, P = 0.00414). Kaplan‒Meier survival analysis also revealed that an eGFR ≥ 169.21 mL/min/1.73 m2 was associated with a greater likelihood of poor outcomes (P = 0.0092). Elevated eGFR is associated with an increased risk of poor clinical outcomes in community-acquired BM in children.